Godavari Drugs Limited successfully concluded its 1st Extra-Ordinary General Meeting (EGM) for FY 2025-26 on February 12, 2026, with shareholders demonstrating strong support for the company's capital raising initiatives. The meeting, conducted through video conferencing in compliance with regulatory guidelines, saw overwhelming approval for two critical special resolutions.

Meeting Overview and Participation

The EGM commenced at 11:00 AM (IST) and concluded at 11:30 AM (IST), including additional time for e-voting. A total of 46 members attended the meeting through video conferencing, ensuring adequate quorum for the proceedings.

Board and Key Personnel Attendance

The meeting was chaired by Mr. Ghanshyam Jaju, Chairman and Non-Executive Director. All directors and key management personnel participated through video conferencing, demonstrating comprehensive leadership engagement.

Resolutions and Voting Results

Shareholders considered two special resolutions, both receiving exceptional support with 99.9998% votes in favor. The voting process combined remote e-voting (conducted from February 09-11, 2026) and insta-poll facilities during the meeting.

Resolution 1: Equity Shares on Preferential Basis

Resolution 2: Convertible Warrants on Preferential Basis

The second resolution regarding convertible warrants issuance to promoters achieved identical voting results, with 4360720 votes in favor out of 4360729 total votes polled, representing 99.9998% approval.

Scrutinizer Oversight and Compliance

Mrs. Vidya Harkut from VSS & Associates, a practicing Company Secretary (Membership No. 7086), served as the appointed scrutinizer. She was responsible for supervising both the remote e-voting process and the electronic voting system during the meeting, ensuring compliance with Section 108 of the Companies Act, 2013 and SEBI regulations.

The scrutinizer confirmed that all voting procedures were conducted in accordance with regulatory requirements, with proper safeguards for electronic voting and comprehensive documentation of the process. The voting rights were determined based on the record date of February 05, 2026, with 7416 total shareholders on record.

Regulatory Compliance and Documentation

The company fulfilled all regulatory obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting proceedings, voting results, and scrutinizer's report were properly documented and submitted to BSE Limited within the prescribed timeframe.

The successful completion of the EGM with overwhelming shareholder support positions Godavari Drugs Limited to proceed with its planned capital raising initiatives through preferential equity shares and convertible warrants issuance.

Godavari Drugs announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, along with key corporate decisions during its Board meeting held on February 11, 2026. The pharmaceutical company reported mixed performance with declining revenues but maintained profitability during the quarter.

Financial Performance Overview

The company's financial performance for Q3FY26 showed a revenue decline compared to the previous year, though profitability remained stable.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Godavari Drugs reported revenue from operations of ₹7264.50 lakhs compared to ₹8784.75 lakhs in the corresponding period of the previous year. Net profit for the nine-month period stood at ₹279.84 lakhs, down from ₹348.69 lakhs in the same period last year.

Working Capital Loan Approval

The Board of Directors approved availing a short-term working capital term loan from ICICI Bank Limited to support business operations and new order execution.

The Board has authorized the Directors to finalize terms and conditions and execute necessary documents with the bank for this facility.

Operational Highlights

During Q3FY26, the company reported cost of materials consumed at ₹1664.11 lakhs compared to ₹1958.82 lakhs in Q3FY25. The company benefited from a positive change in inventories of ₹175.95 lakhs, indicating improved inventory management. Employee benefits expense increased to ₹157.66 lakhs from ₹98.35 lakhs in the corresponding quarter last year.

Corporate Governance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors during their meeting held on February 11, 2026. The meeting commenced at 3:30 PM and concluded at 4:30 PM. The results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. The company's paid-up equity share capital remains unchanged at ₹753.05 lakhs with a face value of ₹10 per share.